#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
ADCY4 Atherosclerosis Mouse Study
A laboratory study links endothelial ADCY4 to vascular inflammation and semaglutide effects in cells and mice, not to a new human treatment result.
GLP-1 Drugs and AF in Obesity With CKD
A matched cohort linked GLP-1 receptor agonist use with less one-year atrial fibrillation in non-diabetic adults with obesity and CKD.
GLP-1 Weight-Loss Drugs: Trial Review
A 24-trial network meta-analysis ranked obesity medicines, but high heterogeneity and indirect comparisons limit claims of superiority.
MASH Trials: Resmetirom and Semaglutide
Two phase 3 trials support resmetirom and semaglutide in MASH, but their separate designs do not establish which treatment works better.
Semaglutide and Smoking in HIV
A cohort study linked semaglutide initiation to lower cigarette use among people with HIV, but it cannot show that the medicine caused the change.
Tirzepatide and TLR2 Inflammation in Mice
A mouse and cell study found tirzepatide reduced selected inflammatory responses after a Western diet. It was not a clinical outcomes trial.
Adolescent GLP 1s: The Muscle Gap
A new perspective uses semaglutide trial data to ask how adolescent GLP 1 care should track muscle, bone, and physical function.
Diabetes Drugs and Cardiovascular Outcomes
A 93-trial network meta-analysis linked several diabetes drug classes with fewer cardiovascular events, while indirect comparisons limit treatment rankings.
GLP-1 Use in Serious Mental Illness
A 218,043-person retrospective cohort linked GLP-1 use with lower cardiovascular event and death risks in serious mental illness.
GLP-1 Safety Knowledge: Student Survey
A Saudi pharmacy-student survey found a mean GLP-1 safety knowledge score of 7.6 out of 17, with a 26.5% response rate.
GLP-1 Use Before Bariatric Surgery
An editorial highlights a matched cohort linking prior GLP-1 or tirzepatide use with fewer early cardiorenal events after surgery.
SLIM LIVER: Semaglutide and HIV
SLIM LIVER found improved liver-fat and blood-marker results with semaglutide in people with HIV, but the trial had no control group.